Background: Patients with inflammatory bowel disease (IBD) who receive biologicals frequently experience lack or loss of response. Our aim was to describe the use and efficacy of biological therapy in a tertiary IBD center.
Methods: We included all bio-naive IBD patients who initiated biological therapy between 2010 and 2020 at our centre.
Background: Inflammatory bowel diseases [IBD], which are associated with a high disease burden, are also reported to be accompanied by a high prevalence of psychiatric disorders. However, the literature on IBD and psychiatric disorders has not been reviewed.
Methods: This systematic review followed the PRISMA guidelines, and its protocol was registered at PROSPERO [ID: CRD42020214359].